Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

David Wallace

Deputy Editor

Having previously worked in the European chemicals industry, Dave has now spent almost a decade with Generics bulletin. Bringing his background and education in law to bear on industry litigation - as well as national legislative and regulatory affairs - he also keeps a close eye on corporate strategy, personnel moves, and product pipelines. A regular delegate to industry events and conferences, he has a particular interest in local market developments, maintaining close links with national industry representatives. He also organizes and judges the annual Global Generics & Biosimilars Awards. A French speaker, Dave enjoys music - with a love of the piano - and visual arts.
Advertisement
Set Alert for Articles By David Wallace

Latest From David Wallace

Should US Insulins Be Treated As Biologics?

Against a backdrop of continued outcry over insulin costs in the US and the looming FDA-imposed transition of insulins to biologic status in early 2020, legislators and manufacturers alike are still lobbying for alternative approaches to the essential diabetes treatment.

Regulation Biosimilars

Torrent Gets FDA Warning Letter

Torrent has been told to conduct a comprehensive review of its global manufacturing operations by the US Food and Drug Administration, as the agency sent a warning letter to the Indian firm over its local manufacturing facility in Indrad, Gujarat.

Manufacturing Regulation

Sandoz Breaks Off Digital Deal With Pear

Sandoz has announced that partner Pear Therapeutics will now market alone the reSET and reSET-O digital therapeutics launched by the pair in the US almost a year ago. The move follows Richard Saynor taking charge of Sandoz as part of the Novartis unit’s current transformation.

Strategy Digital Health

French Law Tackles Biologic Originator Tactics

France is seeking to tackle the originator tactic of using low prices for biologic brands in hospitals to snare patients and keep them on the same product once they transition to outpatient care, where prices are much higher.

France Generic Drugs

French Law Tackles Biologic Originator Tactics

France is seeking to tackle the originator tactic of using low prices for biologic brands in hospitals to snare patients and keep them on the same product once they transition to outpatient care, where prices are much higher.

Regulation Biosimilars

Podcast: Celltrion’s Subcutaneous Infliximab And The Future Of Biosimilars

In this podcast discussion, Generics Bulletin’s David Wallace talks to Informa Pharma Consulting’s Duncan Emerton about Celltrion’s CHMP nod for subcutaneous Remsima, the product’s imminent approval and launch, and what it means for the future of biosimilars.

Biosimilars Strategy
See All
Advertisement
UsernamePublicRestriction

Register